ASHP guidelines on medication cost management strategies for hospitals and health systems

American Journal of Health-System Pharmacy

Volumn 65, Issue 14, 2008, Pages 1368-1384

  Rubino, Michael ^a   Hoffman, James M ^a   Koesterer, Larry J ^a   Swendryznski, Robert G ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Control; Costs; Guidelines; Hospitals; Pharmacists, hospital; Pharmacy, institutional, hospital

Indexed keywords

BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG UTILIZATION; HEALTH CARE; HEALTH CARE COST; HOSPITAL; HOSPITAL MANAGEMENT; HOSPITAL PURCHASING; MEDICAL STAFF; PATIENT SAFETY; PHARMACIST; PLANNING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; ARTICLE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; ORGANIZATION AND MANAGEMENT;

COST CONTROL; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG UTILIZATION; ECONOMICS, HOSPITAL; GUIDELINES AS TOPIC; MATERIALS MANAGEMENT, HOSPITAL; PURCHASING, HOSPITAL; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 47749119593     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080021     Document Type: Review

References (50)

1. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63:123-38.
2. Vogenberg FR, ed. Understanding pharmacy reimbursement. Bethesda, MD: American Society of Health-System Pharmacists; 2005:17-42.
3. ASHP Practice Resource Center for Pharmaceutical Reimbursement. www.ashp.org/s_ashp/cat1c.asp?CID=490&DID=532 (accessed 2007 Sep 10).
4. Clinical Initiative Center interviews. The Advisory Board Company. Washington, DC 2000:20-1.
5. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2007. Am J Health-Syst Pharm. 2007; 64:298-314.
6. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures 2004. Am J Health-Syst Pharm. 2004; 61: 145-58.
7. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures 2005. Am J Health-Syst Pharm. 2005; 62: 149-67.
8. Heffler S, Smith S, Keehan S et al. U.S. health spending projections for 2004-2014. Health Aff (Millwood). 2005; W5:74-WS-85.
9. Rough S, Saenz R. Benchmarking and productivity monitoring: practical strategies for pharmacy managers. www.ashp.org/s_ashp/docs/files/ 2004LeadershipSummary.pdf (accessed 2007 Sep 10).
10. May BE, Herrick JD. Evaluation of drug-procurement alternatives. Am J Hosp Pharm. 1984; 41:1373-8.
11. Wetrich JG. Group purchasing: an overview. Am J Hosp Pharm. 1987; 44: 1581-92.
12. Yost RD. New economics of the pharmaceutical supply chain. Am J Health-Syst Pharm. 2005; 62:525-6.
13. Schumock GT, Meek PD, Ploetz PA et al. Economic evaluations of clinical pharmacy services - 1988-1995. Pharmacotherapy. 1996; 16:1188-208.
14. Schumock GT, Butler MG, Meek PD et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23:113-32.
15. Bond CA, Raehl CL, Patry RL. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004; 24:427-40.
16. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health-Syst Pharm. 2005; 62:1596-605.
17. Coalition Working Group. Principles of a sound drug formulary system. In: Hawkins BH, ed. Best practices for hospital & health-system pharmacy. Bethesda, MD: American Society of Health-System Pharmacists; 2005:125-8.
18. American Society of Hospital Pharmacists. ASHP guidelines on formulary system management. Am J Hosp Pharm. 1992; 49:648-52.
19. Gray T, Bertch K, Gait K et al. Guidelines for therapeutic interchange - 2004. Pharmacotherapy. 2005; 25:1666-80.
20. Schachtner JM, Guharoy R, Medicis JJ et al. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health-Syst Pharm. 2002; 59:529-33.
21. Goldwater SH, Milkovich G, Morrison AJ Jr et al. Comparison of therapeutic interchange with standard educational tools for influencing fluoroquinolone prescribing. Am J Health-Syst Pharm. 2001; 58:1740-5.
22. Grace KA, Swiecki J, Hyatt R et al. Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health-Syst Pharm. 2002; 59:1077-82.
23. Steiner MA, Yorgason RZ, Vermeulen LC et al. Patient outcomes after therapeutic interchange of dolasetron for granisetron. Am J Health-Syst Pharm. 2003; 60:1023-8.
24. Stull DM, Bilmes R, Kim H et al. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health-Syst Pharm. 2005; 62:83-7.
25. Bollinger KA, Vermeulen LC, Davis SN et al. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange. Am J Health-Syst Pharm. 2000; 57:368-72.
26. Nelson WW, Vermeulen LC, Geurkink EA et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med. 2000; 160:2491-6.
27. Sodorff MM, Galt KA, Galt MA et al. Patient perceptions of a proton pump inhibitor therapeutic interchange program across the continuum of care. Pharmacotherapy. 2002; 22:500-12.
28. Carroll NV. Formularies and therapeutic interchange: the health care setting makes a difference. Am J Health-Syst Pharm. 1999; 56:467-72.
29. Rodehaver C, Fearing D. Medication reconciliation in acute care: ensuring an accurate drug regimen on admission and discharge. Jt Comm J Qual Patient Saf. 2005; 31:406-13.
30. Gleason KM, Groszek JM, Sullivan C et al. Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients. Am J Health-Syst Pharm. 2004; 61:1689-95.
31. Saunders SM, Tierney JA, Forde JM et al. Implementing a pharmacist-provided discharge counseling service. Am J Health-Syst Pharm. 2003; 60:1101,6,9.
32. American Society of Health-System Pharmacists. ASHP guidelines on the pharmacist's role in the development, implementation, and assessment of critical pathways. Am J Health-Syst Pharm. 2004; 61:939-45.
33. American Society of Health-System Pharmacists therapeutic position statements. www.ashp.org/s_ashp/catlc.asp?CID=516&DID=558 (accessed 2007 Sep 10).
34. American Society of Health-System Pharmacists therapeutic guidelines. www.ashp.org/s_ashp/catlc.asp?CID=516&DID=559 (accessed 2007 Sep 10).
35. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing - 2004. Am J Health-Syst Pharm. 2005; 62:378-90.
36. Safe practices for better healthcare: 2006 Update: A Consensus Report. Washington, DC: National Quality Forum (NQF). 2006: 22.
37. Schumock GT, Nutescu EA, Walton SM et al. Survey of hospital policies regarding low-molecular-weight heparins. Am J Health-Syst Pharm. 2002; 59: 534-8.
38. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
39. Matthay MA. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001; 344:759-62.
40. Thompson CA. High-cost sepsis drug forces pharmacists to weigh patients' future. Am J Health-Syst Pharm. 2002; 59:692,697. News.
41. Dranitsaris G, Spizzirri D, Pitre M et al. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. Int J Technol Assess Health Care. 2001; 17:171-80.
42. Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health-Syst Pharm. 2000; 57:1703-8.
43. Mazzola JL, Belliveau PP, Cheeseman SH. Guidelines for liposomal amphotericin B. Am J Health-Syst Pharm. 2003; 60:1480-1.
44. Bower AN, Tang HM, Guglielmo BJ. Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B. Am J Health-Syst Pharm. 2004; 61: 915-20.
45. Vermeulen LC Jr, Ratko TA, Erstad BL et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995; 155:373-9.
46. Lucarelli CD. Formulary management strategies for type 3 serotonin receptor antagonists. Am J Health-Syst. Pharm. 2003; 60:(10, suppl)S4-S11.
47. Devlin JW. Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations. Am J Health-Syst Pharm. 2005; 62:(10, suppl 2):24-30.
48. Chernin EL. Pharmacoeconomics of inhaled anesthetic agents: considerations for the pharmacist. Am J Health-Syst Pharm. 2004; 61:(suppl 4)S18-S22.
49. Teich JM, Merchia PR, Schmiz JL et al. Effects of computerized physician order entry on prescribing practices. Arch Intern Med. 2000; 160:2741-7.
50. Fischer MA, Lilly CM, Churchill WW et al. An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre. Drug Saf. 2004; 27:1253-61.